Essity


Q225: Pricing leads growth, volume recovery in focus

18/07/25 -"Essity’s Q2 net sales/EBITA missed consensus by 0.9%/5.1%, respectively. Net sales reached SEK 34.19 billion, reflecting a 1.9% organic increase. Adjusted EBITA decreased by 13% to SEK 4.69 ..."

Pages
53
Language
English
Published on
18/07/25
You may also be interested by these reports :
18/07/25
Essity’s Q2 net sales/EBITA missed consensus by 0.9%/5.1%, respectively. Net sales reached SEK 34.19 billion, reflecting a 1.9% organic increase. ...

18/07/25
Puig posted a solid H1 2025 with 7.6% lfl growth, as Q2 sales accelerated to 7.7% lfl. Fragrance growth moderated from the high Q1 base, but this was ...

01/07/25
More than a decade after “Gangnam Style” went viral, South Korea continues to capture global attention through its cultural exports. Today, with ...

17/06/25
Nothing seems to be going right for Societe Bic (Add, France). This consumer goods player (>60% of profits are derived from lighters) is grappling ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO